EVOLUS INC (EOLS) Stock News

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Breaking Down Evolus: 4 Analysts Share Their Views

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

4 Analysts Have This To Say About Evolus

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

The company expects to soon expand from a single-product player to a "multi-product innovator."

Mentions: ABBV

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evolus (NASDAQ:EOLS) just reported results for the second quarter of 2024.Evolu...

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024

EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.

Mentions: ABBV SBUX

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products